间充质干细胞治疗系统性硬化病专家建议  

Mesenchymal stromalcell therapy for systemic sclerosis:expert recommendations

作　　者：南京大学医学院附属鼓楼医院风湿免疫科 孙凌云[2] 梁军[2] 陈子嫣 徐雪 黄赛赛[2] 温利辉 陈群 耿林玉[2] 王丹丹[2] 张华勇[2] Department of Rheumatology and Immunology,Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital;Sun Lingyun(不详;Department of Rheumatology and Immunology,Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital,Nanjing 210008,China)

机构地区：[1]不详 [2]南京大学医学院附属鼓楼医院风湿免疫科,南京210008

出　　处：《中华风湿病学杂志》2025年第2期93-102,共10页Chinese Journal of Rheumatology

基　　金：国家重点研发计划(2020YFA0710800)。

摘　　要：间充质干细胞(MSC)治疗系统性硬化病(SSc)患者的临床数据在不断积累,该治疗方法已被证实安全且有效。为了规范和促进MSC的临床应用,南京鼓楼医院风湿免疫科专家组结合当前最新研究结果,对MSC治疗SSc的相关问题包括适应证、禁忌证、输注途径、输注次数、输注细胞数、输注前用药以及输注后合并用药等方面进行会议讨论并达成以下科学建议,以期对今后的MSC治疗SSc的临床工作提供参考和指导。With the continuous accumulation of clinical data,mesenchymal stromal cell(MSC)therapy has been proven to be safe and effective for patients with systemic sclerosis(SSc).In order to standardize and promote the clinical application of MSCs,the expert group from the Department of Rheumatology and Immunology at Nanjing Drum Tower Hospital convened a meeting to discuss and reach scientific recommendations on various aspects of MSC therapy for SSc,including indications,contraindications,routes of infusion,number of infusions,cell dosage,pre-infusion medication,and post-infusion combination therapy.These recommendations are based on the latest research findings and are intended to provide reference and guidance for future clinical practice of MSC therapy for SSc.

关 键 词：硬皮病 系统性 间充质干细胞 专家建议 

分 类 号：R593.2[医药卫生—内科学]